{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:31:47Z","timestamp":1793309507362,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cgh.2026.09.035","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:19:55Z","timestamp":1792077595000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis"],"prefix":"10.1016","author":[{"given":"Ali","family":"Hajjar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Nemutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Mert","family":"Sahinkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Linton B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.09.035_bib1","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2026.09.035_bib4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cgh.2022.06.032","article-title":"Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis","volume":"21","author":"Huang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ije\/dyu018","article-title":"Cause-specific mortality risk in alcohol use disorder treatment patients: a systematic review and meta-analysis","volume":"43","author":"Roerecke","year":"2014","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cgh.2026.09.035_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib7","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1572-0241.2008.01837.x","article-title":"Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function","volume":"103","author":"Lucey","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.035_bib8","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis","volume":"98","author":"Thompson Coon","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cgh.2026.09.035_bib9","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.035_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hep.29487","article-title":"Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"67","author":"Roberts","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease","volume":"70","author":"Ganne-Carri\u00e9","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2012.09.007","article-title":"Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups","volume":"11","author":"Mancebo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2022.01.027","article-title":"Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication","volume":"77","author":"Mueller","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3350\/cmh.2015.21.3.279","article-title":"Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease","volume":"21","author":"An","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib15","first-page":"401","article-title":"Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis","volume":"70","author":"Nathani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.09.035_bib16","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/hep.31159","article-title":"Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis","volume":"72","author":"Rich","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib17","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cgh.2018.10.031","article-title":"Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis","volume":"17","author":"Choi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","article-title":"Trends in organ donation and transplantation in the United States, 1999-2008","volume":"10","author":"Wolfe","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2026.09.035_bib19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.cgh.2026.09.035_bib20","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3748\/wjg.v22.i10.2993","article-title":"Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.035_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","article-title":"The burden of illness associated with hepatocellular carcinoma in the United States","volume":"50","author":"Lang","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-4733.2008.00448.x","article-title":"Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index","volume":"12","author":"Cheung","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2026.09.035_bib23","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.suronc.2011.10.005","article-title":"Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment","volume":"21","author":"Toro","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.cgh.2026.09.035_bib24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.hpb.2016.06.010","article-title":"Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors","volume":"18","author":"Sucandy","year":"2016","journal-title":"HPB"},{"key":"10.1016\/j.cgh.2026.09.035_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/jlts.2002.31345","article-title":"Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study","volume":"8","author":"Ratcliffe","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2026.09.035_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score\u2013stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.035_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2050640616659024","article-title":"Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: a US population-based study","volume":"5","author":"El-Fattah","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2026.09.035_bib28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","article-title":"Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation","volume":"234","author":"Lencioni","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.cgh.2026.09.035_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"Llovet","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.09.035_bib33","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2018.07.022","article-title":"Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis","volume":"69","author":"Ganne-Carri\u00e9","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib35","article-title":"United States life tables, 2017","volume":"67","author":"Arias","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.cgh.2026.09.035_bib36","first-page":"1","article-title":"Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study","volume":"00","author":"Julien","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0272989X16656165","article-title":"Changing cycle lengths in state-transition models","volume":"36","author":"Chhatwal","year":"2016","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cgh.2026.09.035_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cgh.2023.05.024","article-title":"Hepatocellular carcinoma incidence threshold for surveillance in virologically cured hepatitis C individuals","volume":"22","author":"Chhatwal","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1572-0241.2007.01100.x","article-title":"Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance","volume":"102","author":"Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.035_bib42","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000139","article-title":"Distinctive features and outcomes of hepatocellular carcinoma in patients with alcohol-related liver disease: a US multicenter study","volume":"11","author":"deLemos","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.035_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2018.7105","article-title":"Comparative analysis of nonalcoholic steatohepatitis\u2013versus viral hepatitis\u2013and alcohol-related liver disease\u2013related hepatocellular carcinoma","volume":"17","author":"Hester","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.cgh.2026.09.035_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2005.10.002","article-title":"Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study","volume":"44","author":"El-Serag","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib45","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","article-title":"Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis","volume":"6","author":"Andersson","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jgh3.12462","article-title":"Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis","volume":"5","author":"McPhail","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.cgh.2026.09.035_bib47","doi-asserted-by":"crossref","DOI":"10.3310\/hta19090","article-title":"Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation","volume":"19","author":"Crossan","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cgh.2026.09.035_bib48","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.510270506","article-title":"Cost-effectiveness of ultrasound-guided liver biopsy","volume":"27","author":"Pasha","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-006-9493-6","article-title":"Liver biopsy: is the pain for real or is it only the fear of it?","volume":"52","author":"Akay","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.09.035_bib50","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/hep4.1512","article-title":"Comprehensive health-state utilities in contemporary patients with cirrhosis","volume":"4","author":"Foster","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2026.09.035_bib52","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.29887","article-title":"The high burden of alcoholic cirrhosis in privately insured persons in the United States","volume":"68","author":"Mellinger","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.035_bib53","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2020.12.004","article-title":"Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis","volume":"74","author":"Avance\u00f1a","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.035_bib54","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2468-2667(20)30062-1","article-title":"Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019\u201340: a modelling study","volume":"5","author":"Julien","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.cgh.2026.09.035_bib55","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.09.035_bib56","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.035_bib58","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.035_bib59","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v20.i43.15943","article-title":"Alcohol and hepatocellular carcinoma: a review and a point of view","volume":"20","author":"Testino","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652600738X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652600738X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:53:43Z","timestamp":1793307223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652600738X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"alternative-id":["S154235652600738X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.09.035","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}